logo

For the Inventor, By the Inventor

Taipei, Taiwan

Development Center for Biotechnology


USPTO Granted Patents = 96



Forward Citations = 260

Loading Chart...
Loading Chart...

297 inventors (with patents filed for the assignee):

goldMedal Rey-Yuh Wu (10 out of 11 patents)

silverMedal Chu-Bin Liao (9 out of 9 patents)

bronzeMedal Ta-Tung Yuan (8 out of 8 patents)

4.  Shyh-Fong Chen (8 out of 9 patents)

5.  Shih-Hsien Chuang (7 out of 18 patents)

6.  Mann-Yan Kuo (7 out of 7 patents)

7.  Yu-Yuan Wu (7 out of 50 patents)

8.  Shih-Chong Tsai (6 out of 6 patents)

9.  Yuh-Shan Chung (6 out of 6 patents)

10.  Hsin Tsai (6 out of 6 patents)

11.  Szu-Liang Lai (5 out of 5 patents)

12.  Chih-Yung Hu (5 out of 5 patents)

13.  Chao-Yang Huang (5 out of 8 patents)

14.  Ying-Yung Lok (5 out of 5 patents)

15.  Shao-Zheng Peng (5 out of 5 patents)


Core Competencies:
Antibody-Drug Conjugates
Anti-CD73
Anti-PD-L1
Heterocyclic Compounds
Tyrosine Kinase Inhibitors
Glycoprotein Conjugates
Cancer Therapy
Neurotensin Receptor
Modulators
Plant Extracts
Immunotherapy
Kinase Inhibitors

96 patents:

1. 12448394 - Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors (2025-10-21),
2. 12202899 - Anti-human PD-L1 antibodies and their uses (2025-01-21),
3. 12187806 - Anti-CD73 antibodies and use thereof (2025-01-07),
4. 12091454 - Humanized anti-human neurotensin receptor 1 antibodies and their uses (2024-09-17),
5. 12043668 - Anti-human CSF-1R antibody and uses thereof (2024-07-23),
6. 11998613 - Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof (2024-06-04),
7. 11499139 - Targeted integration sites in Chinese hamster ovary cell genome (2022-11-15),
8. 11407757 - Heterocycle compounds as Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinase inhibitors (2022-08-09),
9. 11384150 - Antibody-drug conjugates and uses thereof (2022-07-12),
10. 11085062 - Processes for preparing glycoprotein-drug conjugates (2021-08-10),
11. 10980853 - Process for preparing a crassocephalum crepidioides extract, extract prepared thereby and use of the extract (2021-04-20),
12. 10947316 - Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof (2021-03-16),
13. 10793542 - Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof (2020-10-06),
14. 10781266 - Antibodies specific to alpha-enolase and uses thereof (2020-09-22),
15. 10781265 - Humanized antibodies against Globo H and uses thereof in cancer treatments (2020-09-22),
The Development Center for Biotechnology, located in Taipei, Taiwan, specializes in advancing antibody therapeutics with a focus on innovative cancer therapies. The organization is engaged in the research and development of antibody-drug conjugates and various monoclonal antibodies, including anti-CD73 and anti-PD-L1, aimed at enhancing treatment efficacy. Additionally, it explores heterocyclic compounds and tyrosine kinase inhibitors, contributing to the broader field of biopharmaceuticals and targeted therapies.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Development Center for Biotechnology
96 Patents

#39 in Taipei

#245 in Taiwan

#8,045 in the World

Taipei, TW
Taipei, Taiwan

Development Center for Biotechnology

Forward Citations = 260

297 inventors:

goldMedal Rey-Yuh Wu (10 out of 11 patents)

silverMedal Chu-Bin Liao (9 out of 9 patents)

bronzeMedal Ta-Tung Yuan (8 out of 8 patents)

4.  Shyh-Fong Chen (8 out of 9 patents)

5.  Shih-Hsien Chuang (7 out of 18 patents)

Please report any incorrect information to [email protected]
Loading…